Stock Analysis
Vext Science Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Vext Science (CSE:VEXT) Full Year 2023 Results
Key Financial Results
- Revenue: US$34.8m (down 1.7% from FY 2022).
- Net income: US$4.40m (down 60% from FY 2022).
- Profit margin: 13% (down from 31% in FY 2022).
- EPS: US$0.027 (down from US$0.079 in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Vext Science EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) exceeded analyst estimates.
Looking ahead, revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 9.1% growth forecast for the Pharmaceuticals industry in Canada.
Performance of the Canadian Pharmaceuticals industry.
The company's shares are down 6.2% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 5 warning signs for Vext Science (1 is potentially serious) you should be aware of.
Valuation is complex, but we're helping make it simple.
Find out whether Vext Science is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About CNSX:VEXT
Vext Science
Through its subsidiaries, operates as an integrated agricultural technology, services, and property management company in the cannabis industry in the United States.
Good value with mediocre balance sheet.